13.有關正常收縮分率心臟衰竭(Heart failure with preserved ejection fraction)的描述何者為誤?
(A)根據文獻[The Candesartan in Heart Failure-Assessment of Mortality and Morbidity (CHARM) Preserved study], Candesartan 可以改善正常收縮分率心臟衰竭病患之所有原因死亡率(all-cause mortality)
(B)根據文獻[ Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial], Irbesartan無法明顯改善正常收縮分率心臟衰竭病患之臨床預後
(C)根據文獻[Digitalis Investigation Group (DIG) trial],毛地黃 (digoxin)在正常收縮分率心臟衰竭病患的治療上,並無幫助.
(D)根據文獻[Study of The Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure (SENIORS) trial], Nebivolol[一種乙狀受體阻斷劑 (beta-blocker)] , 無法改善曾因正常收縮分率心臟衰竭住院年長病患之所有原因死亡率(all-cause mortality)
(E)根據文獻 [the Aldosterone Receptor Blockade in Diastolic Heart Failure (ALDO-DHF) study], Spironolactone 無法改善正常收縮分率心臟衰竭病患的運動量,心衰竭症狀與生活品質.